Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.45 AUD
Change Today 0.00 / 0.00%
Volume 166.2K
BNO On Other Exchanges
Symbol
Exchange
BNO is not on other exchanges.
As of 2:10 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Open
A$0.45
Previous Close
A$0.45
Day High
A$0.45
Day Low
A$0.44
52 Week High
08/28/14 - A$0.69
52 Week Low
02/13/15 - A$0.38
Market Cap
188.2M
Average Volume 10 Days
205.8K
EPS TTM
A$0.01
Shares Outstanding
418.2M
EX-Date
--
P/E TM
39.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited discovers and develops biopharmaceuticals for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. The company develops small molecule and antibody therapeutics in the areas of cancer, anxiety, depression, and Alzheimer's disease. Its oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. The company’s product pipeline includes BNC105, a novel compound in Phase II clinical trials to disrupt the blood vessels that nourish tumours in cancer treatment; and BNC101, a monoclonal antibody that targets cancer stem cells. It is also developing BNC210/IW-2143 for the treatment of anxiety disorders; BNC375, a small molecule therapeutic for the treatment of cognitive impairment in Alzheimers's disease; and Kv1.3 inhibitors for the treatment of inflammatory disorders. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services. It has collaboration, research, and licensing agreements with Ironwood Pharmaceuticals, Inc.; Merck & Co.; Cancer Therapeutics Cooperative Research Center; Genmab A/S; Laboratory Corporation of America; Athena Diagnostics, Inc.; and Genetic Technologies Limited. The company was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (BNO) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$407.6K
Chief Financial Officer
Total Annual Compensation: A$160.8K
Chief Medical Officer
Total Annual Compensation: A$378.9K
Compensation as of Fiscal Year 2014.

bionomics ltd (BNO) Key Developments

Bionomics Files Patent for Use of BNC105 in Combination with PD-1 and CTLA-4 Immuno-Oncology Antibodies

Bionomics Limited announced that it filed a patent application covering the use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer. This new patent is based on important preclinical findings regarding the synergistic effects in preclinical models of a combination of the company's proprietary novel oncology compound BNC105 and antibodies against known immuno-oncology targets. In these preclinical studies animals with MC38 colorectal tumours had 40% inhibition of tumour growth when treated with BNC105 as a monotherapy and 74% inhibition in tumour growth when treated with an antibody targeting PD1. Animals treated with the combination of BNC105 + anti-PD1 therapy experienced greater benefit with 97% inhibition in tumour growth. In addition animals with CT26 colorectal tumours had 27% inhibition of tumour growth when treated with BNC105 as a monotherapy and 14% inhibition in tumour growth when treated with an antibody targeting CTLA4. Animals treated with the combination of BNC105 + anti-CTLA4 therapy experienced greater benefit with 70% inhibition in tumour growth. Bionomics aims to present these data at the Molecular Targets and Cancer Therapeutics conference in November this year.

Bionomics Ltd. Presents at BIO International Convention 2015, Jun-18-2015 11:00 AM

Bionomics Ltd. Presents at BIO International Convention 2015, Jun-18-2015 11:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Deborah Rathjen, Chief Executive Officer, Managing Director and Executive Director.

Bionomics Ltd. Presents at ASX Spotlight Hong Kong Conference, May-28-2015 01:55 PM

Bionomics Ltd. Presents at ASX Spotlight Hong Kong Conference, May-28-2015 01:55 PM. Venue: Island Shangri-La, Pacific Place, Supreme Court Road, Central, Hong Kong, Hong Kong. Speakers: Deborah Rathjen, Chief Executive Officer, Managing Director and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.45 AUD 0.00

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies
 

Industry Analysis

BNO

Industry Average

Valuation BNO Industry Range
Price/Earnings 38.5x
Price/Sales 5.6x
Price/Book 4.1x
Price/Cash Flow 38.5x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.